USF TrialNet Clinical Center

描述（由申请人提供）：1型糖尿病TrialNet的目的是延迟或预防高危人群发生T1 D，并保护T1 D患者的胰岛细胞功能，这些患者具有残留的胰岛细胞。- 通过一个高度协作的网络来发挥细胞功能，该网络旨在识别有T1 D风险的个体，并确定他们是否有资格参加预防试验，并进行“新发”试验。干预试验。USF糖尿病中心一直是佛罗里达大学的一个非常富有成效的附属机构，并与南佛罗里达大学的TrialNet协调中心合作，开发新的方法来增加TrialNet的注册人数。该中心由一个致力于多学科的团队组成，从最先进的，专门的临床和临床研究 为超过1，400名儿童和成人T1 D患者提供服务。此外，它还建立了一个糖尿病护理提供者区域合作网络，可接触到数千名现有和新发T1 D患者。PI的经验，包括担任印第安纳州大学DPT-1区域招募中心主任，印第安纳州大学TrialNet临床中心前主任，以及预防研究途径的主席，以及他与T1 D利益相关者的成功合作，使他能够为TrialNet做出重要贡献，并为他提供了对TrialNet当前局限性和扩展机会的宝贵见解。USF TrialNet临床中心的资助将大大提高他作为指导委员会的投票成员，临床领导委员会的潜在成员以及临床网络中心的合作者参与TrialNet。资金还将使TrialNet在中西部佛罗里达地区的招募工作得以显著扩大，并使尚未开发的高危人群能够利用TrialNet。USF糖尿病中心致力于开展临床研究，寻求改善T1 D的发展，这一点可以从我们的TrialNet筛查活动、糖尿病临床试验数量以及我们与TrialNet TNCC合作开发创新筛查计划的显著增加中得到证明。我们作为TrialNet临床中心的参与将使我们能够代表TrialNet显着扩大我们目前的合作努力。

DESCRIPTION (provided by applicant): The objectives of Type 1 Diabetes TrialNet are to delay or prevent the development of T1D in persons at risk and to preserve ¿-cell function in those with T1D possessing residual ¿-cell function through a highly collaborative network designed to identify individuals at-risk for T1D and to determine their eligibility for- and enrollment into prevention trials and to perform "new- onset" intervention trials. The USF Diabetes Center has been a very productive Affiliate of the University of Florida and has engaged with the TrialNet Coordinating Center at the University of South Florida to develop novel approaches to increase TrialNet enrollment. The Center is comprised of a committed multi-disciplinary team operating from a state-of-the-art, dedicated clinical and clinical research facility serving greater than 1,400 pediatric and adult patients with T1D. In addition, it has established a regional collaborative network of diabetes care providers with access to thousands of additional existing- and new-onset T1D patients. The PI's experience, including roles as the Indiana University DPT-1 Regional Recruitment Center Director, former Director of the Indiana University TrialNet Clinical Center, and as Chair of the Pathway to Prevention Study, and his successful engagement of T1D stakeholders, have enabled him to make vital contributions to TrialNet and has provided him with valuable insight into TrialNet's current limitations and opportunities for expansion. Funding of the USF TrialNet Clinical Center will greatly enhance his involvement in TrialNet as a voting member of the Steering Committee, potential member of the Clinical Leadership Committee, and collaborator of the Clinical Network Hub. Funding will also permit marked expansion of TrialNet recruitment in the West Central Florida region and gain access to hereto for untapped at-risk populations. The USF Diabetes Center's commitment to pursue clinical studies seeking to ameliorate the development of T1D is evidenced by the marked increase in our TrialNet screening activity, the number of our diabetes clinical trails, and our work with the TrialNet TNCC to develop innovative screening initiatives. Our participation as a TrialNet Clinical Center will permit us to markedly expand our current collaborative efforts on behalf of TrialNet.